News & Updates
Filter by Specialty:
Early remdesivir treatment lowers risk of COVID-19 progression
In the treatment of patients with COVID-19, administering remdesivir within 5 days of symptom onset appears to reduce the risk of progression to severe disease, as shown in a study.
Early remdesivir treatment lowers risk of COVID-19 progression
19 Jan 2022Anxiety, depressive symptoms in JIA tied to pain, stress
Moderate to severe symptoms of anxiety and depression have been reported in about one-fourth of children with juvenile idiopathic arthritis (JIA), according to a study. Such symptoms are associated with pain and stress, but not with other disease manifestations.
Anxiety, depressive symptoms in JIA tied to pain, stress
19 Jan 2022CATALYST sparks signals favouring namilumab for COVID-19
In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.
CATALYST sparks signals favouring namilumab for COVID-19
19 Jan 2022Asians bare unique genetic profile of KRAS-mutated NSCLC
Nonsmall cell lung cancer (NSCLC) with mutations in the KRAS gene show a unique genetic and clinical profile in Asian patients relative to Western counterparts, according to a recent study.
Asians bare unique genetic profile of KRAS-mutated NSCLC
19 Jan 2022Zuranolone for sleeplessness promising in early study
The orally bioavailable, investigational neuroactive steroid zuranolone appears to be beneficial in the treatment of insomnia, producing improvements in sleep measures, including sleep efficiency, duration of awakenings, and total sleep time in adults, according to the results of a phase I study.